The month ahead: June’s upcoming events
Crunch time approaches for UroGen.
Lilly urges degrader caution
Meanwhile, the company plays down the risk of Jaypirca’s CLL approval being rescinded.
Lilly’s big Jaypirca test approaches
After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.
A pivotal push from BeiGene
BGB-16673 and BGB-43395 will soon both be in phase 3 trials, BeiGene reveals.
Kyowa joins GSK in Tim-3
Meanwhile, Tango tries again in PRMT5.
FDA red and green lights: January 2025
AstraZeneca bags three of the month’s four oncology approvals.
ASH 2024 – Jaypirca's confirmation, despite no survival
Crossover scuppers Jaypirca's survival benefit, but full approval seems likely.
ASH 2024 – AstraZeneca aims to fix Calquence’s position
But with Brukinsa and degraders looming, will fixed dosing make the difference?
